Keyphrases
Mechanical Properties
100%
Advanced Glycation End Products
100%
Non-enzymatic Glycation
100%
Risedronate
100%
Alendronate
100%
Bone Matrix
45%
High Dose
27%
Bisphosphonates
27%
Cortical Bone
27%
Work to Fracture
27%
Post-yield
27%
Matrix Quality
18%
Organic Matrix
18%
Brittle Bone
18%
Daily Dose
9%
Post-translational Modification
9%
Treatment Dose
9%
Canine Model
9%
Bone Turnover
9%
Tibial
9%
Fracture Resistance
9%
Dose Equivalent
9%
Postmenopausal Osteoporosis
9%
Intracortical
9%
Energy Absorption
9%
Cortical Bone Tissue
9%
Tissue Turnover
9%
Brittle Fracture
9%
Pharmacology, Toxicology and Pharmaceutical Science
Alendronic Acid
100%
Risedronic Acid
100%
Advanced Glycation End Product
100%
Bisphosphonic Acid Derivative
27%
Osteogenesis Imperfecta
18%
Postmenopause Osteoporosis
9%
Canis
9%
Table Salt
9%
Biochemistry, Genetics and Molecular Biology
Advanced Glycation End-Product
100%
Glycation
100%
Drug Megadose
27%
Animal Model
27%
Posttranslational Modification
9%
Cross-Link
9%
Bone Turnover
9%
Canis
9%
Energy Absorption
9%
Radiology Information System
9%
Immunology and Microbiology
Glycation
100%
Bone Matrix
38%
Cortical Bone
30%
Drug Megadose
23%
Bone Tissue
7%
Cross Linking
7%
Protein Processing
7%
Bone Turnover
7%
Canis
7%
Radiology Information System
7%
Energy Absorption
7%
Veterinary Science and Veterinary Medicine
Cortical Bone
100%
Osteogenesis Imperfecta
50%
Dog
25%
Bone Tissue
25%
Canis
25%